Decreased levels of autoantibody against histone deacetylase 3 in patients with systemic sclerosis

Autoimmunity

Volumn 42, Issue 2, 2009, Pages 120-125

  Kuwatsuka, Yutaka ^a   Ogawa, Fumihide ^a   Iwata, Yohei ^a   Komura, Kazuhiro ^a   Muroi, Eiji ^a   Hara, Toshihide ^a   Takenaka, Motoi ^a   Shimizu, Kazuhiro ^a   Hasegawa, Minoru ^b   Fujimoto, Manabu ^b   Sato, Shinichi ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

Autoantibody; HDAC 3; Systemic sclerosis

Indexed keywords

AUTOANTIBODY; HISTONE DEACETYLASE 3; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; RECOMBINANT ENZYME;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; DERMATOMYOSITIS; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SUBSTRATE; FEMALE; FLUOROMETRY; HUMAN; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MALE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

ADULT; AGED; AUTOANTIBODIES; DERMATOMYOSITIS; FEMALE; HISTONE DEACETYLASES; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC;

EID: 58949090655     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.1080/08916930802406300     Document Type: Article

References (40)

1. Sato, S., Hayakawa, I., Hasegawa, M., Fujimoto, M. and Takehara, K. (2003) Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. J Invest Dermatol, 120, pp. 542-547.
2. White, B. (1996) Immunopathogenesis of systemic sclerosis. Rheum Dis Clin North Am, 22, pp. 695-708.
3. Okano, Y. (1996) Antinuclear antibody in systemic sclerosis (scleroderma). Rheum Dis Clin North Am, 22, pp. 709-735.
4. Xu, WS, Parmigiani, RB and Marks, PA (2007) Histone deacetylase inhibitors: Molecular mechanisms of action. Oncogene, 26, pp. 5541-5552.
5. Zhang, X., Wharton, W., Yuan, Z., Tsai, SC, Olashaw, N. and Seto, E. (2004) Activation of the growth-differentiation factor 11 gene by the histone deacetylase (HDAC) inhibitor trichostatin A and repression by HDAC3. Mol Cell Biol, 24, pp. 5106-5118.
6. de Ruijter, AJ, van Gennip, AH, Caron, HN, Kemp, S. and van Kuilenburg, AB (2003) Histone deacetylases (HDACs): Characterization of the classical HDAC family. Biochem J, 370, pp. 737-749.
7. Yang, XJ and Gregoire, S. (2005) Class II histone deacetylases: From sequence to function, regulation, and clinical implication. Mol Cell Biol, 25, pp. 2873-2884.
8. Porcu, M. and Chiarugi, A. (2005) The emerging therapeutic potential of sirtuin-interacting drugs: From cell death to lifespan extension. Trends Pharmacol Sci, 26, pp. 94-103.
9. Mahlknecht, U., Will, J., Varin, A., Hoelzer, D. and Herbein, G. (2004) Histone deacetylase 3, a class I histone deacetylase, suppresses MAPK11-mediated activating transcription factor-2 activation and represses TNF gene expression. J Immunol, 173, pp. 3979-3990.
10. Herranz, M. and Esteller, M. (2006) New therapeutic targets in cancer: The epigenetic connection. Clin Transl Oncol, 8, pp. 242-249.
11. Cress, WD and Seto, E. (2000) Histone deacetylases, transcriptional control, and cancer. J Cell Physiol, 184, pp. 1-16.
12. Glaser, KB, Li, J., Staver, MJ, Wei, RQ, Albert, DH and Davidsen, SK (2003) Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem Biophys Res Commun, 310, pp. 529-536.
13. Johnstone, RW (2002) Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nat Rev Drug Discov, 1, pp. 287-299.
14. Chung, YL, Lee, MY, Wang, AJ and Yao, LF (2003) A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol Ther, 8, pp. 707-717.
15. Piekarz, R. and Bates, S. (2004) A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr Pharm Des, 10, pp. 2289-2298.
16. Huang, L. (2006) Targeting histone deacetylases for the treatment of cancer and inflammatory diseases. J Cell Physiol, 209, pp. 611-616.
17. Bode, KA, Schroder, K., Hume, DA, Ravasi, T., Heeg, K. Sweet, MJ et al. (2007) Histone deacetylase inhibitors decrease Toll-like receptor-mediated activation of proinflammatory gene expression by impairing transcription factor recruitment. Immunology, 122, pp. 596-606.
18. Adcock, IM (2007) HDAC inhibitors as anti-inflammatory agents. Br J Pharmacol, 150, pp. 829-831.
19. Lin, HS, Hu, CY, Chan, HY, Liew, YY, Huang, HP Lepescheux, L. et al. (2007) Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol, 150, pp. 862-872.
20. Huang, N., Katz, JP, Martin, DR and Wu, GD (1997) Inhibition of IL-8 gene expression in Caco-2 cells by compounds which induce histone hyperacetylation. Cytokine, 9, pp. 27-36.
21. Mishra, N., Reilly, CM, Brown, DR, Ruiz, P. and Gilkeson, GS (2003) Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest, 111, pp. 539-552.
22. Reilly, CM, Mishra, N., Miller, JM, Joshi, D., Ruiz, P. Richon, VM et al. (2004) Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid. J Immunol, 173, pp. 4171-4178.
23. Huber, LC, Distler, JH, Moritz, F., Hemmatazad, H., Hauser, T. Michel, BA et al. (2007) Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. Arthritis Rheum, 56, pp. 2755-2764.
24. Shebzukhov, YV, Koroleva, EP, Khlgatian, SV, Belousov, PV, Kuz'mina, KE Radko, BV et al. (2005) Antibody response to a non-conserved C-terminal part of human histone deacetylase 3 in colon cancer patients. Int J Cancer, 117, pp. 800-806.
25. Masi, AT, Rodnan, GP and Medsger, TA (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum, 23, pp. 581-590.
26. LeRoy, EC, Black, C., Fleischmajer, R., Jablonska, S., Krieg, T. Medsger Jr., TA et al. (1988) Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol, 15, pp. 202-205.
27. Tan, EM, Cohen, AS, Fries, JF, Masi, AT, McShane, DJ and Rothfield, NF (1982) The revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum, 25, pp. 1271-1277.
28. Bohan, A. and Peter, JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med, 292, pp. 403-407.
29. Bohan, A. and Peter, JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med, 292, pp. 344-347.
30. Sato, S., Hasegawa, M., Fujimoto, M., Tedder, TF and Takehara, K. (2000) Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol, 165, pp. 6635-6643.
31. Miyakawa, H., Kikuchi, K., Kitazawa, E. and Kawaguchi, N. (2002) Anti-pyruvate dehydrogenase complex-E2 antibody immunoglobulin class switch from IgM to IgG in long-term follow-up patients with primary biliary cirrhosis. Hepatol Res, 22, pp. 167-173.
32. Liu, S., Cerutti, A., Casali, P. and Crow, MK (2004) Ongoing immunoglobulin class switch DNA recombination in lupus B cells: Analysis of switch regulatory regions. Autoimmunity, 37, pp. 431-443.
33. Phan, TG, Amesbury, M., Gardam, S., Crosbie, J., Hasbold, J. Hodgkin, PD et al. (2003) B cell receptor-independent stimuli trigger immunoglobulin (Ig) class switch recombination and production of IgG autoantibodies by anergic self-reactive B cells. J Exp Med, 197, pp. 845-860.
34. Nishida, K., Komiyama, T., Miyazawa, S., Shen, ZN, Furumatsu, T. Doi, H. et al. (2004) Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression. Arthritis Rheum, 50, pp. 3365-3376.
35. Stephanie Gu, Y, Kong, J., Cheema, GS, Keen, CL, Wick, G. and Gershwin, ME (2008) The Immunobiology of Systemic Sclerosis. Semin Arthritis Rheum, 38, pp. 132-160.
36. Shoenfeld, Y. and Toubi, E. (2005) Protective autoantibodies: Role in homeostasis, clinical importance, and therapeutic potential. Arthritis Rheum, 52, pp. 2599-2606.
37. Shoenfeld, Y. and Isenberg, DA (1989) The mosaic of autoimmunity. Immunol Today, 10, pp. 123-126.
38. Bootsma, H., Spronk, PE, Hummel, EJ, de Boer, G., ter Borg, EJ Limburg, PC et al. (1996) Anti-double stranded DNA antibodies in systemic lupus erythematosus: Detection and clinical relevance of IgM-class antibodies. Scand J Rheumatol, 25, pp. 352-359.
39. Tarkowski, A. and Westberg, G. (1987) Rheumatoid factor isotypes and renal disease in systemic lupus erythematosus. Scand J Rheumatol, 16, pp. 309-312.
40. Malik, S., Bruner, GR, Williams-Weese, C., Feo, L., Scofield, RH Reichlin, M. et al. (2007) Presence of anti-La autoantibody is associated with a lower risk of nephritis and seizures in lupus patients. Lupus, 16, pp. 863-866.